Enveric Biosciences Stock Performance
| ENVB Stock | USD 1.41 0.04 2.92% |
On a scale of 0 to 100, Enveric Biosciences holds a performance score of 4. The firm shows a Beta (market volatility) of 1.52, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Enveric Biosciences will likely underperform. Please check Enveric Biosciences' expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether Enveric Biosciences' price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Enveric Biosciences are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Enveric Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:15 | Dividend Date 2019-11-25 | Ex Dividend Date 2008-04-23 | Last Split Date 2025-01-29 |
1 | Acquisition by Joseph Tucker of 98866 shares of Enveric Biosciences subject to Rule 16b-3 | 05/08/2025 |
2 | Enveric Biosciences Explores New Path with Neurodegenerative Drug Patent ENVB Stock News | 05/20/2025 |
3 | Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 ENVB ... | 05/28/2025 |
4 | Enveric Receives U.S. Patent for Sleep, CNS Therapeutics - Insider Monkey | 06/04/2025 |
5 | Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders | 06/10/2025 |
6 | Acquisition by Dewitt Sheila of 27845 shares of Enveric Biosciences subject to Rule 16b-3 | 06/13/2025 |
7 | Enveric Biosciences Announces Participation in 2025 BIO International Convention ENVB Stock News | 06/16/2025 |
8 | Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003 | 06/24/2025 |
9 | Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder | 07/15/2025 |
10 | Enveric Biosciences Inc. Stock Analysis and Forecast - Free Trend-Following Techniques - jammulinksnews.com | 07/18/2025 |
| Begin Period Cash Flow | 2.3 M |
Enveric Biosciences Relative Risk vs. Return Landscape
If you would invest 129.00 in Enveric Biosciences on April 23, 2025 and sell it today you would earn a total of 12.00 from holding Enveric Biosciences or generate 9.3% return on investment over 90 days. Enveric Biosciences is currently generating 0.2013% in daily expected returns and assumes 3.4051% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Enveric, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Enveric Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enveric Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Enveric Biosciences, and traders can use it to determine the average amount a Enveric Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0591
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ENVB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.41 actual daily | 30 70% of assets are more volatile |
Expected Return
| 0.2 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Enveric Biosciences is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enveric Biosciences by adding it to a well-diversified portfolio.
Enveric Biosciences Fundamentals Growth
Enveric Stock prices reflect investors' perceptions of the future prospects and financial health of Enveric Biosciences, and Enveric Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enveric Stock performance.
| Return On Equity | -1.79 | ||||
| Return On Asset | -0.84 | ||||
| Current Valuation | (3.81 M) | ||||
| Shares Outstanding | 2.47 M | ||||
| Price To Book | 0.83 X | ||||
| Price To Sales | 0.08 X | ||||
| Gross Profit | 8.15 M | ||||
| EBITDA | (9.23 M) | ||||
| Net Income | (9.57 M) | ||||
| Cash And Equivalents | 18.01 M | ||||
| Cash Per Share | 11.44 X | ||||
| Total Debt | 1.49 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.33 X | ||||
| Book Value Per Share | 1.58 X | ||||
| Cash Flow From Operations | (7.73 M) | ||||
| Earnings Per Share | (11.05) X | ||||
| Market Capitalization | 3.26 M | ||||
| Total Asset | 3.08 M | ||||
| Retained Earnings | (106.07 M) | ||||
| Working Capital | 1.24 M | ||||
About Enveric Biosciences Performance
By analyzing Enveric Biosciences' fundamental ratios, stakeholders can gain valuable insights into Enveric Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Enveric Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Enveric Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (86.74) | (82.40) | |
| Return On Tangible Assets | (3.15) | (3.31) | |
| Return On Capital Employed | (6.05) | (5.74) | |
| Return On Assets | (3.11) | (3.26) | |
| Return On Equity | (6.01) | (5.71) |
Things to note about Enveric Biosciences performance evaluation
Checking the ongoing alerts about Enveric Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enveric Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enveric Biosciences may become a speculative penny stock | |
| Enveric Biosciences had very high historical volatility over the last 90 days | |
| Enveric Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (9.57 M) with profit before overhead, payroll, taxes, and interest of 8.15 M. | |
| Enveric Biosciences currently holds about 18.01 M in cash with (7.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Enveric Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Enveric Biosciences Inc. Stock Analysis and Forecast - Free Trend-Following Techniques - jammulinksnews.com |
- Analyzing Enveric Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enveric Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Enveric Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enveric Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enveric Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enveric Biosciences' stock. These opinions can provide insight into Enveric Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Enveric Stock analysis
When running Enveric Biosciences' price analysis, check to measure Enveric Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enveric Biosciences is operating at the current time. Most of Enveric Biosciences' value examination focuses on studying past and present price action to predict the probability of Enveric Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enveric Biosciences' price. Additionally, you may evaluate how the addition of Enveric Biosciences to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |